Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies

Joanna Y. Wang, Chetan Bettegowda

Research output: Contribution to journalArticle

Abstract

Recent work in genetics has identified essential driver mutations in gliomas and has profoundly changed our understanding of tumorigenesis. New insights into the molecular basis of glioma has informed the development of therapies demonstrating considerable potential, including immunotherapeutic approaches such as peptide and dendritic cell vaccines against EGFRvIII. However, the selective targeting of one component of a dysregulated pathway may be inadequate for a durable clinical response, given the intratumoral heterogeneity of glioblastoma (GBM) and hypermutated profiles displayed by tumor recurrences. Immune checkpoint blockade with anti-cytotoxic T lymphocyte antigen-4 (CTLA) and anti-programmed cell death 1 (PD-1) have demonstrated encouraging results in clinical trials with other solid tumors, and recent data suggest that this type of therapy may be particularly useful for tumors with high mutational burdens. Although the survival for patients with GBM has remains grim, the use of immunotherapy may finally change patient outcomes.

Original languageEnglish (US)
Pages (from-to)373-383
Number of pages11
JournalJournal of Neuro-Oncology
Volume123
Issue number3
DOIs
StatePublished - Feb 21 2015

Fingerprint

Glioma
Immunotherapy
Glioblastoma
CTLA-4 Antigen
Neoplasms
Dendritic Cells
Carcinogenesis
Cell Death
Vaccines
Clinical Trials
Recurrence
Mutation
Survival
Therapeutics
epidermal growth factor receptor VIII
Thomsen-Friedenreich antibodies

Keywords

  • EGFRvIII
  • Glioblastoma
  • Glioma
  • IDH1
  • Immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Genetics and immunotherapy : using the genetic landscape of gliomas to inform management strategies. / Wang, Joanna Y.; Bettegowda, Chetan.

In: Journal of Neuro-Oncology, Vol. 123, No. 3, 21.02.2015, p. 373-383.

Research output: Contribution to journalArticle

@article{06036bb6c0bc4a609c29e41c72622f3f,
title = "Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies",
abstract = "Recent work in genetics has identified essential driver mutations in gliomas and has profoundly changed our understanding of tumorigenesis. New insights into the molecular basis of glioma has informed the development of therapies demonstrating considerable potential, including immunotherapeutic approaches such as peptide and dendritic cell vaccines against EGFRvIII. However, the selective targeting of one component of a dysregulated pathway may be inadequate for a durable clinical response, given the intratumoral heterogeneity of glioblastoma (GBM) and hypermutated profiles displayed by tumor recurrences. Immune checkpoint blockade with anti-cytotoxic T lymphocyte antigen-4 (CTLA) and anti-programmed cell death 1 (PD-1) have demonstrated encouraging results in clinical trials with other solid tumors, and recent data suggest that this type of therapy may be particularly useful for tumors with high mutational burdens. Although the survival for patients with GBM has remains grim, the use of immunotherapy may finally change patient outcomes.",
keywords = "EGFRvIII, Glioblastoma, Glioma, IDH1, Immunotherapy",
author = "Wang, {Joanna Y.} and Chetan Bettegowda",
year = "2015",
month = "2",
day = "21",
doi = "10.1007/s11060-015-1730-4",
language = "English (US)",
volume = "123",
pages = "373--383",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Genetics and immunotherapy

T2 - using the genetic landscape of gliomas to inform management strategies

AU - Wang, Joanna Y.

AU - Bettegowda, Chetan

PY - 2015/2/21

Y1 - 2015/2/21

N2 - Recent work in genetics has identified essential driver mutations in gliomas and has profoundly changed our understanding of tumorigenesis. New insights into the molecular basis of glioma has informed the development of therapies demonstrating considerable potential, including immunotherapeutic approaches such as peptide and dendritic cell vaccines against EGFRvIII. However, the selective targeting of one component of a dysregulated pathway may be inadequate for a durable clinical response, given the intratumoral heterogeneity of glioblastoma (GBM) and hypermutated profiles displayed by tumor recurrences. Immune checkpoint blockade with anti-cytotoxic T lymphocyte antigen-4 (CTLA) and anti-programmed cell death 1 (PD-1) have demonstrated encouraging results in clinical trials with other solid tumors, and recent data suggest that this type of therapy may be particularly useful for tumors with high mutational burdens. Although the survival for patients with GBM has remains grim, the use of immunotherapy may finally change patient outcomes.

AB - Recent work in genetics has identified essential driver mutations in gliomas and has profoundly changed our understanding of tumorigenesis. New insights into the molecular basis of glioma has informed the development of therapies demonstrating considerable potential, including immunotherapeutic approaches such as peptide and dendritic cell vaccines against EGFRvIII. However, the selective targeting of one component of a dysregulated pathway may be inadequate for a durable clinical response, given the intratumoral heterogeneity of glioblastoma (GBM) and hypermutated profiles displayed by tumor recurrences. Immune checkpoint blockade with anti-cytotoxic T lymphocyte antigen-4 (CTLA) and anti-programmed cell death 1 (PD-1) have demonstrated encouraging results in clinical trials with other solid tumors, and recent data suggest that this type of therapy may be particularly useful for tumors with high mutational burdens. Although the survival for patients with GBM has remains grim, the use of immunotherapy may finally change patient outcomes.

KW - EGFRvIII

KW - Glioblastoma

KW - Glioma

KW - IDH1

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84937519118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937519118&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1730-4

DO - 10.1007/s11060-015-1730-4

M3 - Article

C2 - 25697584

AN - SCOPUS:84937519118

VL - 123

SP - 373

EP - 383

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -